Technology identity: The role of sociotechnical representations in the adoption of medical devices

Ulucanlar, Selda; Faulkner, Alex; Peirce, Susan Caroline; Elwyn, Glyn

doi:10.1016/j.socscimed.2013.09.008

Cited by 64 publications

(48 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the uptake of telemedicine within psychiatry (which was much championed in UK healthcare policy) was resisted by front-line health professionals who felt that it inhibited their ability to provide attentive and effective care [20]. The importance of institutional interests is illustrated with the adoption of a robotic surgical system for prostatectomy by health providers in many parts of the world [21,22]. In the UK, the robotic system has not been recommended by NICE for prostatectomy because as yet there are insufficient data that it offers meaningful clinical or cost advantages over conventional procedures [23].…”

Section: The Challenge Of Technology Adoption In Healthcarementioning

confidence: 99%

“…Despite this, National Health Service (NHS) hospitals -as with other hospitals in Europe -have enthusiastically embraced the technology and have creatively sourced funding to purchase and maintain the system. The principal reason for this is that the high profile of the system as being 'high-tech' and 'futuristic' helped hospitals to publicly position themselves as being at the forefront of medical innovation [21,22]. The robotic system, in other words, had an identity that aligned with institutional interests.…”

Section: The Challenge Of Technology Adoption In Healthcarementioning

confidence: 99%

See 1 more Smart Citation

Anticipating the Clinical Adoption of Regenerative Medicine: Building Institutional Readiness in the UK

2018

View full text Add to dashboard Cite

This perspective paper examines the challenges of implementing regenerative medicine (RM) therapies within hospitals and clinics. Drawing on recent work in the social sciences, the paper highlights dynamics within existing healthcare systems that will present both hindrances and affordances for the implementation of new RM technologies within hospitals and clinics. The paper argues that identifying suitable locations for cell-and gene-therapy treatment centers requires an assessment of their institutional readiness for RM. Some provisional criteria for assessing institutional readiness are outlined, and the paper will suggest that it is necessary to begin developing a program for the phased introduction of RM in the longer term. Regenerative medicine (RM) therapies, particularly those that are commonly referred to as advanced cell and gene therapies, are in many ways significantly different from existing, conventional therapeutic products and techniques [1]. Cell, tissue or gene-based technologies have the potential to provide therapeutic relief for a range of disorders for which there is currently severe unmet clinical need [2], but the sensitivity and complexity of these technologies presents a range of innovation challenges [3], and commentators have suggested that promising RM technologies are particularly susceptible to the 'valley of death' [4]. Many of these challenges relate to upscaling and manufacturing, regulatory requirements, reimbursement and commissioning [5]. These have been well characterized in recent reviews of the RM field [6], and government-supported initiatives such as the UK's Cell and Gene Therapy Catapult have been launched to mitigate these and facilitate commercialization [7]. Recent reports, however, have identified an additional area of concern: the clinical adoption of RM therapies within existing healthcare systems [8,9]. Hospitals and clinics within contemporary healthcare systems have developed systems to accommodate drug-and device-based therapies and surgical interventions, and they may, then, be poorly suited to implementing cell-, tissueand gene-based treatments. There is, in other words, a degree of incommensurability between existing healthcare providers and the exigencies of providing RM therapies [10].A consequence of this mismatch is that potential investors have difficulties envisaging a clear pathway to commercial and clinical success [11]. This uncertainty represents a risk to the momentum that currently characterizes RM in the UK, Canada, various US states and elsewhere. Hence, while the majority of promising RM therapies are still in the early phases of clinical development [12], commentators have argued that it is necessary to address the potential challenges of clinical delivery in the immediate future [8,9,11]. In this vein, this paper examines the challenges of implementing RM technologies within existing systems of delivery, and it offers some guiding reflections on how such challenges may responsibly be managed. RM represents a diverse range of technologies a...

show abstract

Section: The Challenge Of Technology Adoption In Healthcarementioning

confidence: 99%

Section: The Challenge Of Technology Adoption In Healthcarementioning

confidence: 99%

Anticipating the Clinical Adoption of Regenerative Medicine: Building Institutional Readiness in the UK

2018

View full text Add to dashboard Cite

show abstract

“…CTA can satisfy the needs of decision-makers by targeting the loci of value -promises and practices -in real world. Hence, CTA helps overcome the criticism leveled at mainstream HTA of commonly targeting technology in a stand-alone setting, detached from its real-life circumstances [4,10,11,[17][18][19]. By accommodating a systematic exploration of the innovation's real-world value, CTA is well equipped to guide value-based decision-making on complex medical innovations in the early stages.…”

Section: Editorial Abrishami Boer and Horstmanmentioning

confidence: 99%

“…Practices: the 'how' side of value Medical innovations lend their values from their surrounding context and from ways in which they are put to use [5,[10][11][12]. The impact of a medical technology can hardly be regarded as internal to the technology itself.…”

mentioning

confidence: 99%

How can we assess the value of complex medical innovations in practice?

Abrishami

Boer

Horstman

2015

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

“…A particularly promising direction has been to examine the socio technical influences on whether and how technologies enter into use [1,2].…”

Section: Introductionmentioning

confidence: 99%

Medical Technology and Organizational Context: Deep Brain Stimulation for Parkinson Patients

Gisquet¹

2017

PHOA

View full text Add to dashboard Cite

Despite the long history of DBS, it's under lying objectives are still not clear. What can really be expected from this technique? What are its benefits for the patients? This study explores the way in which a medical technique is implemented in interaction with the local environment. Based on several months of fieldwork, the analysis shows how organizations shape the translation of medical techniques, influencing the way physicians use technologies but also influencing desirability and acceptability for patients. Four local organizational dynamics which affect the use of a medical technology have been identified: the sense-making of the medical technology, the involvement in the new technology, the allocation of this resource to patients and the setting of parameters. The results highlight that those organizational settings can have real effects on the patient's experience. This result is significant for the design of public health policies.

show abstract

Technology identity: The role of sociotechnical representations in the adoption of medical devices

Cited by 64 publications

References 34 publications

Anticipating the Clinical Adoption of Regenerative Medicine: Building Institutional Readiness in the UK

Anticipating the Clinical Adoption of Regenerative Medicine: Building Institutional Readiness in the UK

How can we assess the value of complex medical innovations in practice?

Medical Technology and Organizational Context: Deep Brain Stimulation for Parkinson Patients

Contact Info

Product

Resources

About